Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US
All claims against the company in the litigation have now been dismissed.
All claims against the company in the litigation have now been dismissed.
The new facility will be able to handle four times as many patients as the previous facility.
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
The scheme is subject to statutory and regulatory approvals as may be necessary.
Subscribe To Our Newsletter & Stay Updated